Clinical Trial Update: Intrapleural Bevacizumab Injection for Malignant Effusion in Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating intrapleural bevacizumab for malignant pleural effusion in non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Effusion
• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: Haihong Yang, MD, Pricipal investigator | Conditions: Non-small Cell Lung Cancer, Malignant Pleural Effusion | Phase 2 | Status: COMPLETED